ReviewTherapeutic advances in drug safety2019
Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo.
Review in Therapeutic advances in drug safety, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Medication errors in malaria management in children: insights from pharmacovigilance data in the Democratic Republic of Congo.BMC pharmacology & toxicology · 2025Article
- A narrative review of veterinary pharmacovigilance situations and prospects in East African countries.Frontiers in veterinary science · 2024Review
- Article
- Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review.BMJ open · 2023Article
- Comparison of adverse pregnancy and birth outcomes using archival medical records before and during the first wave of the COVID-19 pandemic in Kinshasa, Democratic Republic of Congo: a facility-based, retrospective cohort study.BMC pregnancy and childbirth · 2023Article
- Stakeholders' Perspective on the Integration of Pharmacovigilance Activities into the Eritrean Healthcare System: A Qualitative Study.Risk management and healthcare policy · 2023Article
- Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa.BMC public health · 2022Article
- Baseline assessment of pharmacovigilance activities in four sub-Saharan African countries: a perspective on tuberculosis.BMC health services research · 2021Article
- Ebola and COVID-19 in Democratic Republic of Congo: grappling with two plagues at once.Tropical medicine and health · 2021Article
- Considerations for Establishing Successful Coronavirus Disease Vaccination Programs in Africa.Emerging infectious diseases · 2021Review
- Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.Drug safety · 2020Article
- Adverse drug reaction profile in Amravati region of India: A pharmacovigilance study.Journal of pharmacy & bioallied sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implementation of pharmacovigilance (PV) systems in resource-limited countries is a real endeavor. Despite country- and continent-specific challenges, the Democratic Republic of the Congo (DRC) has been able to develop one of the most active PV systems in the sub-Saharan Africa. The World Health Organization (WHO) regional Office identified the DRC experience to set up a PV system for antimalarial drugs safety monitoring as a 'best practice' that needed to be documented in order to help DRC improve its PV system and to be scaled up in other African countries. In response to the WHO request, a best practices and bottlenecks analysis was conducted in 2015. This analysis was updated in 2018 in the light of the minimum requirements of the WHO to set up a PV system taking into account other guidance for PV systems. The following themes were retained for analysis: (1) creation of the national PV center; (2) implementation of PV in the health system; (3) data collection and analysis; (4) collaboration with public health programs; (5) collaboration with the National Regulatory Authority. Lessons learnt from the DRC experience show that it is possible to implement PV systems in order to promote patients' safety in resource limited sub-Saharan African countries with no guaranteed funding. The ability of national PV centers to collaborate with Public health stakeholders, including public health authorities at all levels as well as public health programs, and to use existing health information systems are considered the main key to success and may substantially reduce the cost of PV activities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.